JeanChristophe Marcoux - Genfit Chief Officer
| GNFT Stock | USD 3.41 0.12 3.40% |
Insider
JeanChristophe Marcoux is Chief Officer of Genfit
| Age | 47 |
| Phone | 33 3 20 16 40 00 |
| Web | https://www.genfit.com |
Genfit Management Efficiency
The company has return on total asset (ROA) of 0.0651 % which means that it generated a profit of $0.0651 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2591 %, meaning that it created $0.2591 on every $100 dollars invested by stockholders. Genfit's management efficiency ratios could be used to measure how well Genfit manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Patrick Amstutz | Molecular Partners AG | 50 | |
| Jasbir Seehra | Keros Therapeutics | 69 | |
| MBA BS | AN2 Therapeutics | 49 | |
| Thomas Schwerzmann | Molecular Partners AG | N/A | |
| Byron JD | Janux Therapeutics | 60 | |
| David Bradshaw | Harmony Biosciences Holdings | N/A | |
| Michael Carruthers | Edgewise Therapeutics | 67 | |
| Man MBA | Adagene | 48 | |
| Jc MD | Adagene | 60 | |
| Mark Meier | Fennec Pharmaceuticals | N/A | |
| Brian MD | Rezolute | 50 | |
| MBA MR | Aerovate Therapeutics | 62 | |
| Michael Alley | AN2 Therapeutics | N/A | |
| Sharon Goldbach | Harmony Biosciences Holdings | N/A | |
| Behrad Derakhshan | Edgewise Therapeutics | 45 | |
| John MBA | Harmony Biosciences Holdings | 57 | |
| Jennifer Lachey | Keros Therapeutics | 51 | |
| Seth Lewis | Molecular Partners AG | N/A | |
| Jeffrey Aronin | Harmony Biosciences Holdings | 57 | |
| Fangyong Du | Adagene | 54 | |
| Eric Devroe | Acrivon Therapeutics, Common | 46 | |
Management Performance
| Return On Equity | 0.26 | ||||
| Return On Asset | 0.0651 |
Genfit Leadership Team
Elected by the shareholders, the Genfit's board of directors comprises two types of representatives: Genfit inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genfit. The board's role is to monitor Genfit's management team and ensure that shareholders' interests are well served. Genfit's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genfit's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Stefanie JD, Chief Affairs | ||
| Pascal Caisey, Chief Officer | ||
| Sakina SayahJeanne, Executive Science | ||
| Dean Hum, COO, Chief Scientific Officer, Member of the Management Board | ||
| Thomas Baetz, Chief Officer | ||
| Pr Staels, CoFounder Board | ||
| JeanChristophe Marcoux, Chief Officer | ||
| Meriam Kabbaj, Chief Officer | ||
| Pascal Prigent, Chief Officer | ||
| Laurent Lannoo, Corporate Affairs | ||
| JeanFrancois Mouney, Chairman of the Management Board, CEO | ||
| John Brozek, Executive Technology | ||
| Stefanie Magner, Chief Affairs | ||
| Emilie Desodt, Executive Resources |
Genfit Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Genfit a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.26 | ||||
| Return On Asset | 0.0651 | ||||
| Profit Margin | 0.28 % | ||||
| Operating Margin | 0.51 % | ||||
| Current Valuation | 189.56 M | ||||
| Shares Outstanding | 49.91 M | ||||
| Shares Owned By Institutions | 0.52 % | ||||
| Number Of Shares Shorted | 60.31 K | ||||
| Price To Earning | 4.72 X | ||||
| Price To Book | 1.66 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Genfit Stock Analysis
When running Genfit's price analysis, check to measure Genfit's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genfit is operating at the current time. Most of Genfit's value examination focuses on studying past and present price action to predict the probability of Genfit's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genfit's price. Additionally, you may evaluate how the addition of Genfit to your portfolios can decrease your overall portfolio volatility.